ARTICLE | Distillery Therapeutics


December 5, 2017 7:34 PM UTC

Mouse studies suggest NMDA receptor antagonists could help treat autism caused by MEF2C haploinsufficiency. In an MEF2C-haploinsufficient mouse model of autism, NitroSynapsin, a memantine-based NMDA receptor antagonist, increased total hippocampal neurons and decreased excitation-inhibition (E/I) synaptic ratio in the hippocampus compared with vehicle. Also in the model, NitroSynapsin decreased cognitive deficits and repetitive behaviors and increased social interaction compared with vehicle. Next steps in collaboration with Panorama Research Inc. include studies of NitroSynapsin to treat autism...

BCIQ Company Profiles

Panorama Research Inc.

BCIQ Target Profiles

NMDA receptor